Prebiotic specialist Clasado Biosciences can now use 11 self-substantiated health claims for the marketing of its gut health-focused low-dose prebiotic, Bimuno GOS, in Colombia.
Some of these claims include:
- Bimuno GOS' activity as a prebiotic
- The ingredient's role in supporting gastrointestinal health
- Bimuno's ability to support the immune system
These health claims are substantiated by 20 clinical studies, and can now be featured on the packaging of products that contain Bimuno GOS within the country.
According to Clasado, Bimuno GOS as a product has access to more than 80 substantiated health claims across a range of international markets — including the key US and Asian markets.
These have been backed by a number of clinical studies, with Bimuno GOS being the most widely studied prebiotic galactooligosaccharide (GOS) currently on the market.
Recently, Clasado has also gained regulatory approval for health claims in Canada and Australia.
Lucie Nagy, General Counsel at Clasado, commented: “Compliance with regulatory standards is paramount in the health and nutrition sector. In short, we’re engaging with a highly proactive market, and health consumers throughout Latin America want to know that there’s robust research and evidence behind the products they buy."
"These health claims not only reinforce the scientific foundation of Bimuno GOS but also add substantial value for product formulators in Colombia. This achievement is a testament to our exceptional regulatory team's hard work and dedication.”